[PRNewswire] CUVET Successfully Developed the First Stem Cell Transplantation
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Technology to Treat Pet Diabetes
(BANGKOK, Dec. 13, 2022 PRNewswire=연합뉴스) For the first time in Thailand, a research team from Chula's Faculty of Veterinary Science (CUVET), led by Assistant Professor Dr. Chenpop Sawangmek in collaboration with Bio ink Co., Ltd., a Chula spinoff company, has successfully developed a method to culture dog pancreatic cells from stem cells and cell transplantation technology to treat diabetes in pets.
Pets, especially cats and dogs, also suffer from diabetes and the current insulin treatment is not effective. Dogs mostly suffer from type-1 diabetes in which the body lacks beta-cells to create insulin, while cats mostly have type-2 diabetes because of a deficiency in insulin secretion or insulin resistance. They need different treatments.
The research focused primarily on type-1 diabetes in dogs.
"We create dog's pancreatic cells or insulin-producing cells (IPCs) from canine mesenchymal stem cells (cMSCs), and developed transplantation technology to replace the damaged cells."When used along with the double encapsulation transplantation technology, this method produces strong cells and prevents rejection from the immune system.
At present, the research team has successfully developed canine cell tissue for stem cell extraction and multiplication, the process of inducting cells, along with transplantation technology, is now ready to be tested in both lab and sick animals. The treatment is expected to be in use in 3 years.
"Stem cells can be adapted for use in various ways. If we can successfully develop cells from stem cells, in the future all organs can be replaced. We are studying these options along with creating prosthetic bones to replace damaged bones or accelerate their repair along with producing eye cornea in collaboration with the faculties of Medicine and Engineering," said Assistant Prof. Dr. Chenpop.
Plans to develop stem-cell products like cell therapy and stem-cell-derived products to treat pets are in the pipeline. Examples are exosome products to treat damaged organs for rehabilitation and repair; treatment for cancer, liver or kidney disease, and diseases stemming from organ deterioration, infections, or illnesses related to the immune system. The products are expected to be tested on lab animals within the year and available commercially within two years.
Continue reading at https://www.chula.ac.th/en/highlight/92729/
For those interested kindly contact https://www.cuvscbic.com/
or https://www.bioinkcu.com/.
Media Contact:
Chulalongkorn University Communication Center
Email: Pataraporn.r@chula.ac.th
Source: Chulalongkorn University Communication Center
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- '채상병특검법' 본회의 통과…野 재강행·與 반발에 정국 급랭(종합) | 연합뉴스
- 22대 국회 개원식 무기한 연기…'지각 신기록' 관측도(종합) | 연합뉴스
- 尹, 김홍일 사퇴 이틀만에 이진숙 지명…공영방송 이사교체 의지(종합) | 연합뉴스
- 시청역 역주행 운전자 "브레이크 밟았으나 딱딱했다"(종합) | 연합뉴스
- "누구도 못 몰아내"…바이든 후보 사퇴론 진화 '48시간 총력전' | 연합뉴스
- 손아카데미 학부모들 "한번도 체벌 없었다"…시민단체 "2차가해"(종합) | 연합뉴스
- 프로야구, 역대 최소 경기 600만 관중 돌파…12년 만의 신기록 | 연합뉴스
- 밤사이 시간당 20~30㎜ 호우…비구름대 빨라 강수시간 짧을 듯 | 연합뉴스
- 의대 증원 놓고 의평원-정부 충돌…'의대 인증' 새 변수 부상 | 연합뉴스
- "출생때부터 몸안 장기 없던 우리아이…의료공백에 내일 두려워" | 연합뉴스